Pfizer Inc. (NYSE:PFE) Shares Sold by Mogy Joel R Investment Counsel Inc.

Mogy Joel R Investment Counsel Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 55,388 shares of the biopharmaceutical company’s stock after selling 8,141 shares during the quarter. Mogy Joel R Investment Counsel Inc.’s holdings in Pfizer were worth $1,595,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Investment Advisory Services Inc. TX ADV grew its position in Pfizer by 1.6% in the third quarter. Investment Advisory Services Inc. TX ADV now owns 20,097 shares of the biopharmaceutical company’s stock worth $667,000 after buying an additional 325 shares during the last quarter. Trifecta Capital Advisors LLC grew its position in Pfizer by 3.7% in the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 325 shares during the last quarter. Powers Advisory Group LLC grew its position in Pfizer by 2.4% in the third quarter. Powers Advisory Group LLC now owns 13,759 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 329 shares during the last quarter. Confluence Wealth Services Inc. grew its position in Pfizer by 0.5% in the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after buying an additional 342 shares during the last quarter. Finally, Carr Financial Group Corp grew its position in Pfizer by 3.3% in the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 355 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Up 0.6 %

Shares of PFE stock traded up $0.14 on Friday, hitting $25.40. The company’s stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37. The firm’s fifty day moving average price is $26.96 and its 200-day moving average price is $28.42. The stock has a market capitalization of $143.83 billion, a price-to-earnings ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the business earned $1.14 EPS. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.61%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is presently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.